Does an FDA HDE help in Latin America? Humanitarian devices at ANVISA, COFEPRIS and INVIMA

An FDA Humanitarian Device Exemption does not qualify for ANVISA optimized review under IN 290/2024, which accepts only 510(k), PMA or De Novo. Mexico and Colombia have no HDE-equivalent device route, their orphan mechanisms cover medicines, and an HDE never replaces ethics or regulator approval for a study. Where the HDE file still helps.

Founders of rare-condition device companies keep asking me the same question, and they usually ask it after a week of reading contradictory answers online: if we hold, or expect to hold, an FDA Humanitarian Device Exemption (HDE), does it shorten anything in Brazil, Mexico or Colombia? And a close second: do those countries have a faster pathway for “orphan” devices?

I’m Julio Martinez-Clark, CEO of bioaccess®. We run first-in-human and early feasibility device studies across Latin America and hold device registrations in the region. Here is the short version, then the detail.

The short answer

  • Brazil (ANVISA): an HDE does not qualify for ANVISA’s optimized reliance review. Instrução Normativa (IN) 290/2024 lists the FDA instruments it accepts by name: 510(k) clearance, PMA, or De Novo under 513(f)(2). HDE is not on that list.
  • Mexico (COFEPRIS): I have not found a published device pathway built around an HDE, and the 2025 abbreviated pathway is designed around reference approvals granted through ordinary review.
  • Colombia (INVIMA): there is no abbreviated equivalency pathway for devices at all, and no HDE-equivalent route.
  • “Orphan” fast tracks: the orphan and rare-disease mechanisms that do exist in Mexico and Colombia are written for medicines, not devices.
  • Clinical studies: in all three countries, an HDE does not replace ethics committee approval or the regulator’s study authorization. What it can do is make your investigational dossier stronger, because the evidence behind it is reusable.

What an HDE actually is, and why that matters abroad

An HDE is an FDA marketing authorization for a Humanitarian Use Device (HUD): a device intended to treat or diagnose a disease or condition that affects not more than 8,000 individuals in the United States per year. The rules sit in 21 CFR Part 814, Subpart H. The defining feature is that the sponsor must show safety and probable benefit, and is exempt from the effectiveness requirements that apply to a PMA. Use at a US facility also requires IRB approval, and there are limits on profit.

That design is exactly why foreign regulators treat it differently. A reliance pathway borrows another agency’s conclusion that a device is safe and effective. An HDE, by construction, is not an effectiveness conclusion. The HUD threshold is also a US population number, so it says nothing about prevalence in Brazil, Mexico or Colombia.

Brazil: why IN 290/2024 does not help an HDE

IN 290/2024 created ANVISA’s optimized analysis for Class III and IV device registrations, based on prior authorization by an equivalent foreign regulatory authority (AREE). Article 6 names the accepted proof for each authority. For the US FDA, it is a 510(k) clearance, a PMA, or a De Novo. Australia, Canada and Japan are the other three AREE. An HDE order is not one of the listed instruments, so an HDE-only device goes through ordinary registration under RDC 751/2022.

Two more points that confuse people:

  • Article 4 excludes devices that the foreign authority authorized through an abbreviated route similar to ANVISA’s own optimized procedure. Even if you argued an HDE into scope, it would face that test.
  • Reliance only shortens the technical review. It never removed the Brazilian registration holder, Portuguese labeling and IFU, ANVISA GMP certification for Class III and IV, or INMETRO where it applies. I cover that in detail in our regional reliance comparison.

For a clinical investigation in Brazil, the operative rule is RDC 837/2023. If your study falls under it, you need ethics approval through the CEP/CONEP system and a DICD (the device clinical investigation dossier) submitted to ANVISA. An HDE does not replace either. Some academic studies are handled differently under RDC 837, which we explain here, but that turns on who sponsors the study, not on the FDA status of the device.

Mexico: what the abbreviated pathway accepts

Mexico has recognized certain foreign device approvals since its 2010 equivalence agreement, and in 2025 COFEPRIS widened this into a general reliance model. The general guidelines for the abbreviated regulatory pathway were published in the Diario Oficial de la Federación on 18 July 2025. Three conditions in that model work against an HDE: the product must be identical to the one the reference authority approved, the reference approval must be valid when you file, and reference approvals granted through something other than an ordinary review cannot support the request.

My practical advice: plan on standard COFEPRIS registration for an HDE-only device. If you think your case is different, get COFEPRIS’s position in writing before you build a launch timeline on it.

On “orphan” status: Article 224 Bis of Mexico’s Ley General de Salud defines medicamentos huérfanos as medicines for rare diseases with a prevalence of no more than 5 per 10,000 inhabitants. It is a medicines definition. I have not found an equivalent orphan category for medical devices.

For a study in Mexico, COFEPRIS authorizes the clinical investigation and an ethics committee and research committee review it, regardless of the device’s FDA status. Insurance is part of the package, and we have written about that timeline.

Colombia: no equivalency route, and the “vital” mechanism is for medicines

INVIMA does not run a formal abbreviated equivalency pathway for devices. An FDA approval is useful evidence in the file, not a substitute for INVIMA’s review, and an HDE carries less weight than a 510(k) or PMA because it is not an effectiveness finding.

The rare-disease mechanism people find when they search Colombia is medicamentos vitales no disponibles under Decreto 481 de 2004. It lets certain essential medicines that are unavailable in the country be imported or sold without a sanitary registration. INVIMA itself notes that Colombia has no “orphan medicine” classification, and the decree covers medicines, not devices.

A device study in Colombia needs ethics committee approval and INVIMA authorization. Our INVIMA clinical trial submission checklist lists what goes in.

Where an HDE does help

None of this means the HDE work is wasted. When we prepare a first-in-human or early feasibility submission in Latin America, the HDE file is a strong source of material:

  • Bench, biocompatibility and sterilization data that already passed FDA review can go straight into the investigator’s brochure and the regulatory dossier.
  • The probable-benefit clinical data supports the risk-benefit section that ethics committees read most closely.
  • The FDA order and labeling show regulators and committees that a reference agency has already looked at the device.

The trade-off is honest: in these three countries, an HDE improves the quality of your file. It does not change which pathway you are on.

A decision rule I give founders

  1. If your US plan ends at HDE, budget ordinary registration in Brazil, Mexico and Colombia.
  2. If a 510(k), De Novo or PMA is realistic later, decide whether LATAM registration should wait for it. In Brazil, that is what unlocks IN 290/2024.
  3. If you need clinical data first, the study pathway is the same with or without an HDE. Pick the country on ethics timelines, site experience in your indication, and patient access, not on the HDE.

FAQ

Does an FDA HDE qualify for ANVISA’s optimized review under IN 290/2024?
No. For the FDA, IN 290/2024 accepts a 510(k), PMA or De Novo. An HDE-only device follows ordinary registration.

Is there an orphan device pathway in Mexico or Colombia?
Not that I have found. Mexico’s orphan definition (Ley General de Salud, Article 224 Bis) and Colombia’s vitales no disponibles mechanism (Decreto 481 de 2004) both cover medicines.

Can an HDE replace ethics or regulatory approval for a clinical study in Latin America?
No. Brazil still requires CEP/CONEP approval and, under RDC 837/2023, a DICD at ANVISA. Mexico and Colombia require ethics approval and regulator authorization.

Is the HDE data useful for a LATAM study?
Yes. The preclinical, biocompatibility and probable-benefit data strengthen the dossier and the ethics committee’s risk-benefit review.

If you are weighing an HDE device for Latin America, either for a study or for registration, our market access team can map the pathway country by country before you commit budget.

This article reflects regulations as published at the time of writing (November 2026). It is general information, not legal advice for a specific device.

← Back to Blog · Contact bioaccess®